Obama administration now favors 12 years of worldwide marketing exclusivity for new biologics (consistent with US policy): http://www.pharmalive.com/white-house-pushes-12-year-exclusivity-for-biologics-in-trade-talks This is a change; previously the Obama administration had lobbied Congress to shorten the 12-year period afforded by the AHA.